Gemcitabine Injection

DRUG13 trials

Sponsors

Tianjin Medical University Cancer Institute and Hospital, Panbela Therapeutics, Inc., British Columbia Cancer Agency, Repare Therapeutics, Fudan University

Conditions

AdultAdvanced Solid TumorLarge B-cell LymphomaMetastatic Breast CancerMetastatic Pancreatic CancerMetastatic Pancreatic Ductal AdenocarcinomaNon-small Cell Lung CancerPancreatic Cancer Metastatic

Phase 1

Study of SBP-101 Combined With Nab-Paclitaxel and Gemcitabine in Pancreatic Cancer

CompletedNCT03412799

Panbela Therapeutics, Inc.Pancreatic Cancer Metastatic, Pancreatic Cancer Stage IV, Stage IV Pancreatic Cancer

Start: 2018-06-04End: 2022-02-28Updated: 2022-05-25

A Study of SLC-0111 and Gemcitabine for Metastatic Pancreatic Ductal Cancer in Subjects Positive for CAIX

TerminatedNCT03450018

British Columbia Cancer AgencyMetastatic Pancreatic Ductal Adenocarcinoma

Start: 2019-01-10End: 2024-05-16Updated: 2024-05-24

Study of RP-3500, Camonsertib, in Advanced Solid Tumors

CompletedNCT04497116

Repare TherapeuticsAdvanced Solid Tumor

Start: 2020-07-22End: 2025-06-13Updated: 2025-10-21

CNCT19 Following ASCT in Patients With Relapsed or Refractory B-cell Lymphoma

CompletedNCT04690192

Institute of Hematology & Blood Diseases Hospital, ChinaLarge B-cell Lymphoma

Start: 2021-01-01End: 2024-12-30Updated: 2025-05-13

Phase 2

Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer

CompletedNCT01631357

Tianjin Medical University Cancer Institute and HospitalNon-small Cell Lung Cancer, Squamous Cell Carcinoma

Start: 2014-12-31End: 2018-12-31Updated: 2019-11-05

Efficacy and Safety of Camrelizumab Combined With Nab-Paclitaxel Plus Gemcitabine for Metastatic Pancreatic Cancer

Fudan UniversityMetastatic Pancreatic Cancer

Start: 2019-08-01End: 2022-12-31Target: 117Updated: 2020-08-04

The ASCEND Study: Gemcitabine and Nab-Paclitaxel With LSTA1 (Certepetide) or Placebo in Patients With Untreated Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruitingNCT05042128

Australasian Gastro-Intestinal Trials GroupMetastatic Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma

Start: 2022-04-13End: 2025-10-01Updated: 2024-10-22

Combined Therapy Using D-TACE, Gemcitabine and Cisplatin, and PD1 Antibody in Advanced and Unresectable Intrahepatic Cholangiocarcinoma

RecruitingNCT05738057

Hua LiUnresectable Intrahepatic Cholangiocarcinoma

Start: 2023-06-30End: 2026-03-01Target: 22Updated: 2023-11-29

Autologous Tumor Infiltrating Lymphocytes (GT101 Injection) in Patients with Recurrent or Metastatic Cervical Cancer

RecruitingNCT06241781

Grit BiotechnologyAdult

Start: 2024-04-02End: 2027-01-31Target: 83Updated: 2025-02-07

Chiauranib in Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma

Active, not recruitingNCT06492915

Chipscreen Biosciences, Ltd.Pancreatic Ductal Adenocarcinoma

Start: 2024-08-13End: 2026-10-31Target: 42Updated: 2026-03-18

Clinical Study of TQB2868 Injection Combined With Anlotinib Capsule and Chemotherapy in the First-line Treatment of Metastatic Pancreatic Neoplasms

RecruitingNCT06767813

Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.Pancreatic Neoplasms

Start: 2024-03-19End: 2026-11-30Target: 80Updated: 2025-09-19

Phase 3

Asian Study of Sacituzumab Govitecan (IMMU-132) in HR+/HER2- Metastatic Breast Cancer (MBC)

Active, not recruitingNCT04639986

Gilead SciencesMetastatic Breast Cancer

Start: 2020-11-23End: 2026-12-01Updated: 2026-02-09

Chiauranib Plus PD-1 Inhibitor, Albumin-paclitaxel and Gemcitabine in Patients With Metastatic Pancreatic Ductal Adenocarcinoma

Not yet recruitingNCT07445295

Chipscreen Biosciences, Ltd.Metastatic Pancreatic Ductal Adenocarcinoma

Start: 2026-03-31End: 2028-11-30Target: 558Updated: 2026-03-03

Related Papers

Camonsertib, an ATRi, in Combination with Low-Dose Gemcitabine in Solid Tumors with DNA Damage Response (DDR) Aberrations: Preclinical and Phase 1b Results.

2026-01-21

Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response-Deficient Tumors.

2025-10-01

Data from Genomic and Epigenomic ctDNA Profiling in Liquid Biopsies from Heavily Pretreated Patients with DNA Damage Response–Deficient Tumors

2025-10-01

TQB2868 combined with anlotinib and nab-paclitaxel plus gemcitabine as first-line treatment for metastatic pancreatic cancer: A prospective, multicenter, single-arm, phase 2 study.

Journal of Clinical Oncology2025-05-28

AGITG ASCEND: Randomised, double-blind phase II study of certepetide or placebo added to gemcitabine plus nab-paclitaxel in patients with untreated metastatic pancreatic ductal adenocarcinoma: Initial results.

Journal of Clinical Oncology2025-01-273 citations

Sacituzumab govitecan in HR<sup>+</sup>HER2<sup>-</sup> metastatic breast cancer: the randomized phase 3 EVER-132-002 trial.

2024-10-0125 citations

Ataxia telangiectasia and Rad3-related (ATR) inhibitor camonsertib dose optimization in patients with biomarker-selected advanced solid tumors (TRESR study)

JNCI Journal of the National Cancer Institute2024-05-069 citations

Population Pharmacokinetics of Sacituzumab Govitecan in Patients with Metastatic Triple-Negative Breast Cancer and Other Solid Tumors.

2024-04-0517 citations

XELOX (capecitabine plus oxaliplatin) plus bevacizumab (anti-VEGF-A antibody) with or without adoptive cell immunotherapy in the treatment of patients with previously untreated metastatic colorectal cancer: a multicenter, open-label, randomized, controlled, phase 3 trial.

2024-04-0321 citations

Combinational therapy of CAR T-cell and HDT/ASCT demonstrates impressive clinical efficacy and improved CAR T-cell behavior in relapsed/refractory large B-cell lymphoma

Journal for ImmunoTherapy of Cancer2024-04-0125 citations

Discovery of the Potent and Selective ATR Inhibitor Camonsertib (RP-3500)

Journal of Medicinal Chemistry2024-02-0121 citations

Abstract B001: Identification of monoallelic <i>ATM</i> loss-of-function and homologous recombination deficiency (HRD) in high-grade ovarian tumor with prolonged response to camonsertib and low-dose gemcitabine combination therapy

Cancer Research2024-01-091 citations

Abstract B026: Detection and characterization of DDR reversion alterations in baseline tissue and plasma samples from patients enrolled in the TRESR and ATTACC Phase I clinical trials

Cancer Research2024-01-09

Abstract B025: Exceptional response to the ataxia telangiectasia and Rad3-related inhibitor (ATRi), camonsertib, in a patient with alternative lengthening of telomeres (ALT)-positive metastatic melanoma

Cancer Research2024-01-09

Development of a Practical Nomogram for Personalized Anemia Management in Patients Treated with Ataxia Telangiectasia and Rad3-related Inhibitor Camonsertib

Clinical Cancer Research2023-12-115 citations

Abstract A123: Circulating tumor DNA (ctDNA) genomic and epigenomic profiling (GuardantINFINITY) for diagnosis of DNA damage repair (DDR) loss of function (LOF) and response monitoring in the TRESR and ATTACC trials

Molecular Cancer Therapeutics2023-12-011 citations

Abstract B045: Ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in combination with low dose gemcitabine in patients with solid tumors with DNA damage response (DDR) aberrations: Preclinical and Phase 1b results

Molecular Cancer Therapeutics2023-12-01

Camonsertib in DNA damage response-deficient advanced solid tumors: phase 1 trial results.

2023-06-0567 citations

ASCEND: A randomised, double-blinded, phase II study of gemcitabine and nab‐paclitaxel with CEND‐1/LSTA1 or placebo in patients with untreated metastatic pancreatic ductal adenocarcinoma.

Journal of Clinical Oncology2023-06-01

Abstract CT018: Safety and efficacy of three PARP inhibitors (PARPi) combined with the ataxia telangiectasia- and Rad3-related kinase inhibitor (ATRi) camonsertib in patients (pts) with solid tumors harboring DNA damage response (DDR) alterations

Cancer Research2023-04-147 citations

13 more papers not shown